文献速递眼底病与葡萄膜炎神经眼科

阿尔茨海默病的视网膜改变:影像、功能与分子进展的综合展望

Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances.
PubMed 文献 · Prog Retin Eye Res · 2020-09-02

本文综述阿尔茨海默病(AD)视网膜改变的研究现状,指出AD神经病理在临床诊断前多年即已启动,现有影像、认知、脑脊液和血液生物标志物在症状期敏感性和特异性差异大,早期应用受限。视网膜可及性高,功能和结构、代谢及血管改变及淀粉样蛋白、tau沉积等机制在人及动物研究中被识别,分子影像进展使监测视网膜生化改变和蛋白聚集病理成为可能,未来需整合分子影像与功能结构改变以评估视网膜标志物效用。

要点

  • AD神经病理在临床诊断前多年即已启动,早期生物标志物需求迫切。
  • 视网膜可及性高,早期AD已见功能、结构、代谢和血管改变。
  • 人及动物研究提示视网膜存在淀粉样蛋白和tau沉积等生化改变。

核心结论

  • 视网膜功能和结构、代谢及血管改变及分子影像监测的生化改变,有望作为AD潜在生物标志物,但尚需整合研究评估其效用。

研究设计与样本

  • 本文为综述,汇总现有关于AD视网膜影响的知识并指出需解决的空白。

主要发现

  • AD神经病理过程在临床体征出现和诊断前数年甚至数十年即已启动。
  • 现有影像、认知、脑脊液和血液生物标志物在症状期敏感性和特异性差异大,早期应用难以论证。
  • 研究已识别AD早期视网膜可测量的功能、结构、代谢和血管改变。
  • 近期人及动物模型研究提供视网膜生化通路改变的机制见解,包括淀粉样蛋白和tau沉积。

临床怎么用

  • 眼科智能体医生可关注AD患者视网膜功能、结构、代谢和血管改变的评估潜力。
  • 分子影像监测视网膜生化改变和蛋白聚集病理是AD研究的探索方向。

局限性

  • 现有生物标志物在症状期敏感性和特异性差异大,早期应用受限。
  • 视网膜改变作为AD生物标志物的效用尚未确立,需未来研究整合分子影像与功能结构改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder of the brain, clinically characterised by cognitive deficits that gradually worsen over time. There is, at present, no established cure, or disease-modifying treatments for AD. As life expectancy increases globally, the number of individuals suffering from the disease is projected to increase substantially. Cumulative evidence indicates that AD neuropathological process is initiated several years, if not decades, before clinical signs are evident in patients, and diagnosis made. While several imaging, cognitive, CSF and blood-based biomarkers have been proposed for the early detection of AD; their sensitivity and specificity in the symptomatic stages is highly variable and it is difficult to justify their use in even earlier, pre-clinical stages of the disease. Research has identified potentially measurable functional, structural, metabolic and vascular changes in the retina during early stages of AD. Retina offers a distinctively accessible insight into brain pathology and current and developing ophthalmic technologies have provided us with the possibility of detecting and characterising subtle, disease-related changes. Recent human and animal model studies have further provided mechanistic insights into the biochemical pathways that are altered in the retina in disease, including amyloid and tau deposition. This information coupled with advances in molecular imaging has allowed attempts to monitor biochemical changes and protein aggregation pathology in the retina in AD. This review summarises the existing knowledge that informs our understanding of the impact of AD on the retina and highlights some of the gaps that need to be addressed. Future research will integrate molecular imaging innovation with functional and structural changes to enhance our knowledge of the AD pathophysiological mechanisms and establish the utility of monitoring retinal changes as a potential biomarker for AD.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Gupta VB, Chitranshi N, den Haan J, et al. Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res. 2020. PMID: 32890742. doi:10.1016/j.preteyeres.2020.100899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。